Introduction {#sec1-0300060520910019}
============

On a global scale, cancer is the main public health problem and liver cancer is a major contributor to both cancer morbidity and mortality.^[@bibr1-0300060520910019]^ Liver cancer is the sixth most common cancer and the fourth highest cause of cancer-related mortality worldwide.^[@bibr2-0300060520910019]^ There were expected to be 42,030 newly diagnosed cases and 31,780 deaths of liver cancer in the United States during 2019.^[@bibr3-0300060520910019]^ Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, comprising 75% to 85% of cases.^[@bibr2-0300060520910019]^ The well-recognized risk factors for HCC include chronic infection with hepatitis B (HBV) or hepatitis C virus, exposure to dietary aflatoxin, alcohol-induced cirrhosis, smoking, obesity, and type 2 diabetes.^[@bibr2-0300060520910019],[@bibr4-0300060520910019]^ In Asia (especially China), chronic HBV infection is the leading etiologic factor of HCC.^[@bibr5-0300060520910019]^ Most HCC patients are diagnosed at an advanced stage, and locoregional treatments (chemoembolization) and surgical treatments are relatively disappointing in terms of overall survival (OS) of patients with advanced disease.^[@bibr6-0300060520910019]^ In addition, traditional chemotherapies have not shown promising outcomes in treatment of HCC and have significant toxicity.^[@bibr6-0300060520910019],[@bibr7-0300060520910019]^ Meanwhile, the lack of early detection of diagnostic markers and limited treatment strategies increase the risk of poor prognosis and death.^[@bibr8-0300060520910019]^ Therefore, there is a pressing need to develop robust diagnostic strategies and effective therapies for HCC patients.^[@bibr9-0300060520910019]^

Over the past decades, microarray technology and bioinformatics have been extensively applied to identify the molecular mechanisms of HCC, which provide strong research support for the diagnosis, treatment, and prognosis of HCC.^[@bibr10-0300060520910019]^ Because of the ability to process a large number of datasets quickly, integrated bioinformatics analysis and microarray technology have allowed researchers to comprehensively identify the functions of numerous differentially expressed genes (DEGs) in HCC, and they help researchers explore the complicated process of HCC occurrence and development.^[@bibr10-0300060520910019],[@bibr11-0300060520910019]^ A work by He et al.^[@bibr12-0300060520910019]^ identified four hub genes and two important pathways in the development of HCC from cirrhosis from one Gene Expression Omnibus (GEO) dataset using a bioinformatics method, including DEG screening, enrichment analyses, and construction of a protein--protein interaction (PPI) network. Zhang et al.^[@bibr13-0300060520910019]^ screened hub genes and pathways correlated with the occurrence and progression of HCC via a series of bioinformatics analyses incorporating DEGs identification, functional enrichment analyses, PPI network and module analysis, and weighted correlation network analysis. Zhou et al.^[@bibr11-0300060520910019]^ identified the pivotal genes and microRNAs in HCC using a bioinformatics approach, including analysis of raw data via GEO2R, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, and construction of PPI network. However, to improve the diagnosis and treatment of HCC, novel diagnostic and prognostic biomarkers for HCC are needed. The flowchart of the study approach is shown in [Figure 1](#fig1-0300060520910019){ref-type="fig"}.

![Flowchart for identification of core genes and pathways for hepatocellular carcinoma (HCC). GEO, Gene Expression Omnibus; DEG, differentially expressed gene; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPI, protein--protein interaction; GEPIA, Gene Expression Profiling Interactive Analysis.](10.1177_0300060520910019-fig1){#fig1-0300060520910019}

Materials and methods {#sec2-0300060520910019}
=====================

Ethical approval {#sec3-0300060520910019}
----------------

Ethical approval was not required in this study because we analyzed only published data from the GEO database.

Gene expression profile data {#sec4-0300060520910019}
----------------------------

Gene expression profile data (GSE36376,^[@bibr14-0300060520910019]^ GSE39791,^[@bibr15-0300060520910019]^ GSE41804,^[@bibr16-0300060520910019]^ GSE54236,^[@bibr17-0300060520910019],[@bibr18-0300060520910019]^ GSE57957,^[@bibr19-0300060520910019]^ GSE62232,^[@bibr20-0300060520910019]^ GSE64041,^[@bibr21-0300060520910019]^ GSE69715,^[@bibr22-0300060520910019]^ GSE76427,^[@bibr23-0300060520910019]^ GSE84005, GSE87630,^[@bibr24-0300060520910019]^ GSE112790,^[@bibr25-0300060520910019]^ and GSE121248^[@bibr26-0300060520910019]^) were downloaded from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>),^[@bibr27-0300060520910019]^ a public data repository, including high-throughput gene expression and other functional genome datasets. The selection criteria for the included datasets were as follows: (1) tissue samples collected from human HCC and corresponding adjacent or normal tissues; and (2) including at least 40 samples.

Integrated analysis of microarray datasets {#sec5-0300060520910019}
------------------------------------------

The matrix data of each GEO dataset were normalized and log~2~ transformed using the R software package limma,^[@bibr28-0300060520910019]^ and the DEGs between HCC and corresponding adjacent or normal tissues were also filtered using the limma package. Integration of DEGs identified from the 13 datasets was performed by RobustRankAggreg package^[@bibr29-0300060520910019]^ in R software. A \|log~2~ fold change (FC)\| ≥1 and adjusted *P*-value \< 0.05 were considered significant for the DEGs.

Enrichment analyses of DEGs {#sec6-0300060520910019}
---------------------------

Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/>, version, 6.8)^[@bibr30-0300060520910019]^ is a comprehensive functional annotation tool for extracting biological significance from large gene/protein datasets. In this study, the GO and KEGG pathway enrichment analyses for the DEGs were conducted via DAVID. The visualization of enrichment analysis results was conducted by using ggplot2^[@bibr31-0300060520910019]^ and the GOplot^[@bibr32-0300060520910019]^ package in the R software.

PPI network and module analysis {#sec7-0300060520910019}
-------------------------------

Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; <https://string-db.org/>)^[@bibr33-0300060520910019]^ is a database of known and predicted protein interactions, showing direct and indirect interactions among proteins. This database was applied to obtain potential interactions among the DEGs. PPIs with a confidence score ≥0.7 were reserved and imported into Cytoscape software^[@bibr34-0300060520910019]^ to construct the PPI network. Furthermore, the clustering modules in this PPI network were analyzed using the MCODE (Molecular Complex Detection) plugin in Cytoscape.^[@bibr35-0300060520910019]^ Pathway enrichment analyses for important modules were also carried out. The visualization of enrichment analysis results was performed by using the imageGP platform (<http://www.ehbio.com/ImageGP/index.php/Home/Index/GOenrichmentplot.html>).

Survival analysis of hub genes {#sec8-0300060520910019}
------------------------------

Kaplan--Meier plotter (KM plotter; <http://kmplot.com/analysis/>) is a database containing clinical data and gene expression data.^[@bibr36-0300060520910019]^ This database is used to further understanding the molecular basis of disease and identifying biomarkers associated with survival.^[@bibr37-0300060520910019]^ The recurrence-free survival and OS information were based on GEO, the European Genome-phenome Archive (EGA), and The Cancer Genome Atlas (TCGA) databases. Hazard ratios (HR) with 95% confidence intervals and log rank *P*-value were calculated to assess the association of gene expression with survival and are shown in plots.^[@bibr38-0300060520910019]^

Expression level analysis and correlation analysis of hub genes {#sec9-0300060520910019}
---------------------------------------------------------------

The Gene Expression Profiling Interactive Analysis (GEPIA; [http://gepia.cancer pku.cn/index.html](http://gepia.cancerpku.cn/index.html))^[@bibr39-0300060520910019]^ is a newly developed web-based tool that applies a standard processing pipeline to analyze gene expression data between tumor and normal tissues. The relationship of expression of hub genes in HCC and normal tissues were visualized by boxplot.^[@bibr38-0300060520910019]^ In addition, correlation analysis was performed by GEPIA to check the relative ratios between two genes.^[@bibr39-0300060520910019]^

Results {#sec10-0300060520910019}
=======

Identification of DEGs {#sec11-0300060520910019}
----------------------

In the present study, 13 datasets were downloaded from GEO that included 1100 cancer tissues and 717 corresponding adjacent or normal tissues ([Table 1](#table1-0300060520910019){ref-type="table"}). After integrated analysis, 380 DEGs (293 downregulated and 87 upregulated) were identified ([Figure 2a-m](#fig2-0300060520910019){ref-type="fig"} and Appendix). [Figure 2n](#fig2-0300060520910019){ref-type="fig"} shows the top 20 down- and upregulated genes.

###### 

Information for the 13 Gene Expression Omnibus datasets included in the current study.

![](10.1177_0300060520910019-table1)

  Dataset     Platform                                                                                     Number of samples (tumor/control)
  ----------- -------------------------------------------------------------------------------------------- -----------------------------------
  GSE36376    GPL10558-Illumina HumanHT-12 V4.0 expression beadchip                                        433 (240/193)
  GSE39791    GPL10558-Illumina HumanHT-12 V4.0 expression beadchip                                        144 (72/72)
  GSE41804    GPL570-\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        40 (20/20)
  GSE54236    GPL6480-Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name version)       161 (81/80)
  GSE57957    GPL10558-Illumina HumanHT-12 V4.0 expression beadchip                                        78 (39/39)
  GSE62232    GPL570-\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        91 (81/10)
  GSE64041    GPL6244-\[HuGene-1_0-st\] Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\]   125 (60/65)
  GSE69715    GPL570-\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        103 (37/66)
  GSE76427    GPL10558-Illumina HumanHT-12 V4.0 expression beadchip                                        167 (115/52)
  GSE84005    GPL5175-\[HuEx-1_0-st\] Affymetrix Human Exon 1.0 ST Array \[transcript (gene) version\]     76 (38/38)
  GSE87630    GPL6947-Illumina HumanHT-12 V3.0 expression beadchip                                         94 (64/30)
  GSE112790   GPL570-\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        198 (183/15)
  GSE121248   GPL570-\[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array                        107 (70/37)

![Identification of DEGs. Volcano plots of Gene Expression Omnibus datasets (a) GSE36376, (b) GSE39791, (c) GSE41804, (d) GSE54236, (e) GSE57957, (f) GSE62232, (g) GSE64041, (h) GSE69715, (i) GSE76427, (j) GSE84005, (k) GSE87630, (l) GSE112790, and (m) GSE121248; (n) heat map of DEGs. Blue indicates lower expression levels, red indicates higher expression levels, and white indicates no differentially expression among the genes. Each column represents one dataset and each row represents one gene. The number in each rectangle represents the normalized gene expression level. The gradual color ranged from blue to red represents the changing process from downregulation to upregulation. DEG, differentially expressed gene.](10.1177_0300060520910019-fig2){#fig2-0300060520910019}

GO and KEGG pathway enrichment analyses of DEGs {#sec12-0300060520910019}
-----------------------------------------------

To deepen our understanding of DEGs, we performed GO and KEGG pathway enrichment analyses. Thirty-one significantly enriched GO terms were selected based on a false discovery rate (FDR) \< 0.05 ([Figure 3a](#fig3-0300060520910019){ref-type="fig"} and Appendix). In the GO terms were 13 terms for biological process, mainly related to metabolic process, P450 pathway, and oxidation-reduction process; 12 terms for molecular function, highly involved with multiple enzyme activities, heme binding, iron ion binding and oxygen binding; and 6 terms for cellular components, associated with organelle membrane, extracellular exosome, extracellular region, extracellular space, blood microparticle, and membrane attack complex.

![Enrichment analysis of DEGs. (a) GO enrichment analysis of DEGs, (b) top 5 terms of GO enrichment, and (c) KEGG pathway analysis of DEGs. DEG, differentially expressed gene; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.](10.1177_0300060520910019-fig3){#fig3-0300060520910019}

In the KEGG pathway enrichment analyses, we screened nine pathways according to FDR \< 0.05. [Figure 3c](#fig3-0300060520910019){ref-type="fig"} shows the results of KEGG analysis; the DEGs primarily participated in diverse metabolism-associated signaling pathways, such as metabolic pathways, retinol metabolism, drug metabolism-cytochrome P450, among others.

PPI network establishment and module analysis {#sec13-0300060520910019}
---------------------------------------------

The PPI network of DEGs comprised 242 nodes and 1267 interactions ([Figure 4a](#fig4-0300060520910019){ref-type="fig"}); degree was calculated to identify candidate key nodes. Finally, 11 potential key nodes were identified, the degrees of which were all more than four times the corresponding average values: *CDK1*, *CCNB2*, *CDC20*, *CCNB1*, *TOP2A*, *CCNA2*, *MELK*, *PBK*, *TPX2*, *KIF20A*, and *AURKA* ([Table 2](#table2-0300060520910019){ref-type="table"}). Moreover, to determine important clustering modules in the PPI network, module analysis was performed using MCODE, and the two modules with the highest scores (score \>10) were obtained ([Figure 4b, 4c](#fig4-0300060520910019){ref-type="fig"}). The enrichment pathways of module 1 and module 2 are shown in [Figure 5](#fig5-0300060520910019){ref-type="fig"}. Module 1 was highly associated with cell cycle and oocyte meiosis; module 2 was closely connected to drug metabolism-cytochrome P450, linoleic acid metabolism, chemical carcinogenesis, arachidonic acid metabolism, retinol metabolism, metabolism of xenobiotics by cytochrome P450, and metabolic pathways.

![PPI network and hub clustering modules. (a) The PPI network of DEGs, (b) module 1 (MCODE score = 38.769), and (c) module 2 (MCODE score = 10.364). Blue circles represent downregulated genes and red circles represent upregulated genes. PPI, protein--protein interaction; DEG, differentially expressed gene; MCODE, Molecular Complex Detection.](10.1177_0300060520910019-fig4){#fig4-0300060520910019}

###### 

Upregulated hub genes with high degrees.

![](10.1177_0300060520910019-table2)

  Gene       Degree   Type   MCODE Cluster
  ---------- -------- ------ ---------------
  *CDK1*     47       up     Module 1
  *CCNB2*    46       up     Module 1
  *CDC20*    45       up     Module 1
  *CCNB1*    45       up     Module 1
  *TOP2A*    44       up     Module 1
  *CCNA2*    44       up     Module 1
  *MELK*     43       up     Module 1
  *PBK*      43       up     Module 1
  *TPX2*     43       up     Module 1
  *KIF20A*   43       up     Module 1
  *AURKA*    43       up     Module 1

![Pathway analysis of the two modules with the highest scores. The y-axis shows significantly enriched KEGG pathways, and x-axis shows the two modules. KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.](10.1177_0300060520910019-fig5){#fig5-0300060520910019}

Survival analysis, expression, and correlation analysis of hub genes {#sec14-0300060520910019}
--------------------------------------------------------------------

Survival analysis of 11 hub genes was performed using the KM plotter. The results showed that high expression of *CDK1* (HR = 2.15, 95% CI: 1.52--3.06; *P* = 1.1e−05), *CCNB2* (HR = 1.91, 95% CI: 1.28--2.87; *P* = 0.0013), *CDC20* (HR = 2.49, 95% CI: 1.72--3.59; *P* = 5.1e−07), *CCNB1* (HR = 2.34, 95% CI: 1.55--3.54; *P* = 3.4e−05), *TOP2A* (HR = 1.99, 95% CI: 1.39--2.86; *P* = 0.00012), *CCNA2* (HR = 1.92, 95% CI: 1.36--2.72; *P* = 0.00018), *MELK* (HR = 2.22, 95% CI: 1.5--3.27; *P* = 3.7e−05), *PBK* (HR = 2.24, 95% CI: 1.5--3.34; *P* = 4.8e−05), *TPX2* (HR = 2.29, 95% CI: 1.62--3.24; *P* = 1.4e−06), *KIF20A* (HR = 2.33, 95% CI: 1.63--3.32; *P* = 1.8e−06), and *AURKA* (HR = 1.77, 95% CI: 1.25--2.5; *P* = 0.0011) was related to unfavorable OS for HCC patients ([Figure 6](#fig6-0300060520910019){ref-type="fig"}). Furthermore, GEPIA was adopted to analyze the different expression level of hub genes in HCC and normal tissues and the 11 hub genes were confirmed to be highly expressed in HCC tissues ([Figure 7](#fig7-0300060520910019){ref-type="fig"}). The correlations between hub genes were also analyzed by GEPIA, which showed that the 11 hub genes were significantly correlated with each other. [Figure 8](#fig8-0300060520910019){ref-type="fig"} showed that the increase in expression of *CDK1* was strongly associated with increased expression of the other 10 hub genes.

![Prognostic roles of 11 hub genes in patients with HCC shown as survival curves. (a) *CDK1*, (b) *CCNB2*, (c) *CDC20*, (d) *CCNB1*, (e) *TOP2A*, (f) *CCNA2*, (g) *MELK*, (h) *PBK*, (i) *TPX2*, (j) *KIF20A*, and (k) *AURKA*. HCC, hepatocellular carcinoma; HR, hazard ratio.](10.1177_0300060520910019-fig6){#fig6-0300060520910019}

![Analysis of expression levels of 11 hub genes in human HCC. The red and gray boxes represent cancer and normal tissues, respectively. (a) *CDK1*, (b) *CCNB2*, (c) *CDC20*, (d) *CCNB1*, (e) *TOP2A*, (f) *CCNA2*, (g) *MELK*, (h) *PBK*, (i) *TPX2*, (j) *KIF20A*, and (k) *AURKA*. HCC, hepatocellular carcinoma; LIHC, liver hepatocellular carcinoma.](10.1177_0300060520910019-fig7){#fig7-0300060520910019}

![Correlation analysis of 10 hub genes in HCC with *CDK1*: (a) *CCNB2*, (b) *CDC20*, (c) *CCNB1*, (d) *TOP2A*, (e) *CCNA2*, (f) *MELK*, (g) *PBK*, (h) *TPX2*, (i) *KIF20A*, and (j) *AURKA*. HCC, hepatocellular carcinoma.](10.1177_0300060520910019-fig8){#fig8-0300060520910019}

Discussion {#sec15-0300060520910019}
==========

HCC is the most common type of malignancy and one of the leading causes of cancer-related mortality worldwide.^[@bibr40-0300060520910019],[@bibr41-0300060520910019]^ Although much research has been done on HCC, its early diagnosis and treatment remains difficult because of a lack of understanding of the molecular mechanisms associated with HCC occurrence and development.^[@bibr41-0300060520910019]^ Therefore, in-depth studies of the etiological factors and molecular mechanisms of HCC are of critical importance for HCC diagnosis and treatment.^[@bibr11-0300060520910019]^ Currently, bioinformatics analysis and microarray technology are developing rapidly and this approach can be used to identify therapeutic targets for diagnosis, therapy, and prognosis of a variety of neoplasms.^[@bibr42-0300060520910019]^ In this research, we identified 380 DEGs, including 293 downregulated and 87 upregulated genes, between HCC and corresponding adjacent or normal tissues. Enrichment analyses indicated that the DEGs were mostly associated with metabolic processes, such as metabolism of retinol, drugs, xenobiotics, tyrosine, tryptophan, and histidine, as well as fatty acid degradation. This indicated that metabolic dysregulation is closely related to HCC. In addition, we obtained 11 hub genes (*CDK1*, *CCNB2*, *CDC20*, *CCNB1*, *TOP2A*, *CCNA2*, *MELK*, *PBK*, *TPX2*, *KIF20A*, and *AURKA*) in the PPI network, which were upregulated in HCC tissues compared with normal tissues; expression of the first hub gene, *CDK1*, was strongly correlated with that of the other hub genes. Overexpression of the 11 hub genes was correlated with worse OS.

Recent evidence implies that tumor cells need specific interphase cyclin-dependent kinases (CDKs) to proliferate.^[@bibr43-0300060520910019]^ Cyclin-dependent kinase 1 (CDK1) belongs to the CDK family, a member of the serine/threonine protein kinases, and it is crucial for the cell cycle phase transitions G~1~/S and G~2~/M.^[@bibr44-0300060520910019],[@bibr45-0300060520910019]^ CDK1 is required for cell proliferation because it is the only CDK that can initiate mitosis.^[@bibr46-0300060520910019]^ The deregulation of CDK1 is likely related to HCC tumorigenesis.^[@bibr47-0300060520910019]^ Research has found that high expression of CDK1 is correlated with poor OS of HCC.^[@bibr45-0300060520910019]^ Cyclins act as the regulatory subunits of the CDKs, regulating temporal transitions among various stages of the cell cycle via CDK activation.^[@bibr48-0300060520910019]^ Cyclin-A2 (CCNA2), cyclin-B1 (CCNB1), and cyclin-B2 (CCNB1), encoded by the *CCNA2*, *CCNB1*, and *CCNB2* genes, respectively, all belong to the cyclin family. CCNA2 activates CDK1 at the end of interphase to facilitate the onset of mitosis, and *CCNA2* overexpression has been reported in numerous types of cancers.^[@bibr49-0300060520910019]^ A previous study indicated that CCNA2 amplification and overexpression is associated with carcinogenesis of transgenic mouse liver tumors.^[@bibr50-0300060520910019]^ Moreover, research has demonstrated that inhibition of CCNA2 can arrest HCC cell proliferation and tumorigenesis.^[@bibr51-0300060520910019]^ High expression of *CCNA2* is associated with reduced survival in patients with breast cancer and HCC.^[@bibr52-0300060520910019],[@bibr53-0300060520910019]^ CCNB1 and CCNB2 are the principal activators of CDK1 and, together with CDK1, they promote the G~2~/M transition.^[@bibr54-0300060520910019],[@bibr55-0300060520910019]^ Expression of *CCNB1* changes periodically throughout the cell cycle, and is a crucial initiator of mitosis.^[@bibr56-0300060520910019]^ Decreased *CCNB1* expression is related to inhibition of HCC occurrence and development, and activation of *CCNB1* expression can promote proliferation in human HCC cells.^[@bibr56-0300060520910019],[@bibr57-0300060520910019]^ Furthermore, previous research has shown that CCNB1 is closely connected to prognosis of HCC patients. ^[@bibr56-0300060520910019],[@bibr58-0300060520910019]^ The dimerization of *CCNB2* with *CDK1* is an essential component of the cell cycle regulatory machinery, and an increase in expression of *CCNB2*/*CDK1* could promote tumor cell proliferation.^[@bibr55-0300060520910019]^ Furthermore, *CCNB2* is highly expressed in several malignant tumors and overexpression of *CCNB2* is related to poor prognosis in HCC.^[@bibr59-0300060520910019]^ Cell division cycle protein 20 (encoded by *CDC20*) is a regulator of cell cycle checkpoints, which plays a crucial role in anaphase initiation and exit from mitosis.^[@bibr60-0300060520910019],[@bibr61-0300060520910019]^ It degrades several important substrates, including cyclin A and CCNB1, to regulate cell cycle progression.^[@bibr62-0300060520910019],[@bibr63-0300060520910019]^ *CDC20* overexpression is related to progression and poor prognosis in various malignant tumors.^[@bibr64-0300060520910019][@bibr65-0300060520910019][@bibr66-0300060520910019]--[@bibr67-0300060520910019]^ Thus, it is a potential target in multiple cancer treatments.^[@bibr68-0300060520910019]^ A recent study found that increased expression of *CDC20* is related to HCC development and progression.^[@bibr67-0300060520910019]^ Additionally, research has indicated that silencing expression of *CDC20* and heparanase can activate cell apoptosis; thus, targeting inhibition of both *CDC20* and heparanase expression is an ideal approach for the treatment of HCC.^[@bibr69-0300060520910019]^

Aurora kinase A (encoded by *AURKA*) is involved in centrosome duplication, spindle formation, chromosomal amplification and segregation, and cytokinesis, and it plays a significant role in centrosome maturation and mitotic commitment in the late G~2~ phase.^[@bibr70-0300060520910019],[@bibr71-0300060520910019]^ Abnormal activity of *AURKA* promotes tumorigenic progression and transformation via defective control at the checkpoint of mitotic spindle.^[@bibr72-0300060520910019]^ Meanwhile, *AURKA* is highly expressed in a variety of human cancers, including breast cancer,^[@bibr73-0300060520910019]^ lung cancer,^[@bibr74-0300060520910019]^ gastrointestinal cancer,^[@bibr75-0300060520910019]^ bladder cancer,^[@bibr76-0300060520910019]^ and oral cancer.^[@bibr77-0300060520910019]^ A study demonstrated that genetic variations in *AURKA* might be a reliable predictor of early-stage HCC and a crucial biomarker for HCC development.^[@bibr78-0300060520910019]^ Moreover, other research has indicated that *AURKA* contributes in metastasis and invasiveness of HCC.^[@bibr79-0300060520910019]^ Therefore, *AURKA* might represent a new therapeutic target for HCC. Topoisomerase II alpha (TOP2A), a potential biomarker for cancer therapy, has been detected in various types of cancer.^[@bibr80-0300060520910019][@bibr81-0300060520910019]--[@bibr82-0300060520910019]^ It participates in chromosome condensation and chromatid separation.^[@bibr80-0300060520910019]^ *TOP2A* encodes topoisomerase II alpha^[@bibr81-0300060520910019]^ and is reported to be overexpressed in HCC tissues.^[@bibr83-0300060520910019]^ Furthermore, a study has shown that *TOP2A* has prognostic value in HCC and its reactive agents can be used in HCC therapy.^[@bibr84-0300060520910019]^ Maternal embryonic leucine zipper kinase (encoded by *MELK*) is a member of the AMP protein kinase family of serine/threonine kinases, which affect many stages of tumorigenesis.^[@bibr85-0300060520910019]^ Several studies have shown that MELK is an oncogenic kinase essential for early HCC recurrence, and its expression is upregulated in HCC.^[@bibr86-0300060520910019][@bibr87-0300060520910019]--[@bibr88-0300060520910019]^ Furthermore, MELK inhibition is associated with suppression of tumor growth, indicating that MELK is a potential therapeutic target for HCC.^[@bibr89-0300060520910019]^ PDZ-binding kinase (encoded by *PBK*) can regulate cell cycle processes.^[@bibr90-0300060520910019]^ Although PBK is barely detectable in normal somatic tissues, it is often elevated in various tumor tissues and is therefore an important target for cancer screening and targeted therapy.^[@bibr91-0300060520910019],[@bibr92-0300060520910019]^ Recent research has shown that PBK overexpression promotes migration and invasion of HCC, and it could be a therapeutic target for HCC metastasis.^[@bibr93-0300060520910019]^ Targeting protein for Xklp2 (TPX2) expression is modulated by the cell cycle, and it is detected in G~1~/S phase and disappears after cytokinesis.^[@bibr94-0300060520910019],[@bibr95-0300060520910019]^ Several studies have indicated that *TPX2* is highly expressed in different types of cancers.^[@bibr96-0300060520910019],[@bibr97-0300060520910019]^ Additionally, expression of *TPX2* is related to proliferation and apoptosis in HCC.^[@bibr98-0300060520910019]^ *TPX2* overexpression promotes the growth and metastasis of HCC.^[@bibr99-0300060520910019]^ Kinesin family member 20A (KIF20A) is required during mitosis for the final step of cytokinesis.^[@bibr100-0300060520910019],[@bibr101-0300060520910019]^ Studies have found that high expression of KIF20A is correlated with progression or poor prognosis of many types of cancers.^[@bibr102-0300060520910019][@bibr103-0300060520910019]--[@bibr104-0300060520910019]^ Furthermore, *KIF20A* is aberrantly expressed in HCC tissues and its expression may be associated with poor OS.^[@bibr105-0300060520910019]^

According to enrichment analyses of two modules, we found that module 1 was mostly associated with cell cycle and module 2 was closely related to metabolic pathways. Furthermore, all 11 hub genes belonged to module 1 and most are associated with cell cycle and enriched in the "cell cycle" pathway. A number of studies have elucidated that cell cycle disorders are closely related to human cancer.^[@bibr43-0300060520910019]^ Therefore, the carcinogenesis and progression of HCC may be associated with the cell cycle pathway, and we might be able to suppress HCC cell cycle progression, inhibit HCC cell proliferation, and reduce HCC malignancy by downregulating expression of the 11 hub genes identified herein.

Compared with previous studies, this work has several advantages, as follows. First, the current integrated microarray data used a relatively large sample size from several GEO datasets (GSE36376,^[@bibr14-0300060520910019]^ GSE39791,^[@bibr15-0300060520910019]^ GSE41804,^[@bibr16-0300060520910019]^ GSE54236,^[@bibr17-0300060520910019],[@bibr18-0300060520910019]^ GSE57957,^[@bibr19-0300060520910019]^ GSE62232,^[@bibr20-0300060520910019]^ GSE64041,^[@bibr21-0300060520910019]^ GSE69715,^[@bibr22-0300060520910019]^ GSE76427,^[@bibr23-0300060520910019]^ GSE84005, GSE87630,^[@bibr24-0300060520910019]^ GSE112790,^[@bibr25-0300060520910019]^ and GSE121248^[@bibr26-0300060520910019]^). Second, functional enrichment analyses were performed to identify the main biological functions and pathways regulated by DEGs. Third, we established PPI networks, conducted module analysis, discovered potential biomarkers for diagnosis and prognosis of HCC, and performed correlation analysis of hub genes.

The limitations of this work were as follows: First, our results need to be verified by corresponding experimental studies. Second, we obtained data from the GEO database, and data quality cannot be verified. Finally, our study focused on genes that are typically identified as significant changes in diverse datasets, without regard to sex, age, or grading and staging of tumors from which the samples were derived.

Conclusion {#sec16-0300060520910019}
==========

In the present work, we identified 11 hub genes (*CDK1*, *CCNB2*, *CDC20*, *CCNB1*, *TOP2A*, *CCNA2*, *MELK*, *PBK*, *TPX2*, *KIF20A*, and *AURKA*) associated with the development and poor prognosis of HCC by integrated bioinformatics analysis. However, because our study was based on data analysis only, further experiments are required to confirm the results. Our findings will provide evidence and new insights to enhance approaches for the early diagnosis, prognosis, and treatment of HCC.
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Information for 293 downregulated genes (down) and 87 upregulated genes (up).
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  Name         logFC      Type   Name          logFC      Type   Name          logFC       Type
  ------------ ---------- ------ ------------- ---------- ------ ------------- ----------- ------
  *CLEC1B*     −3.33713   down   *IL13RA2*     −1.41685   down   *CSRNP1*      −1.20759    down
  *C9*         −2.93972   down   *PAMR1*       −1.30729   down   *ZGPAT*       −1.283655   down
  *FCN3*       −3.32589   down   *CYP26A1*     −1.82557   down   *FAM150B*     −1.096361   down
  *CYP1A2*     −3.61576   down   *JCHAIN*      −1.90133   down   *LPA*         −1.568535   down
  *HAMP*       −3.72675   down   *ADIRF*       −1.34189   down   *ALPL*        −1.135143   down
  *SLCO1B3*    −2.84405   down   *NNMT*        −1.65555   down   *S100A8*      −1.149369   down
  *SPP2*       −2.19217   down   *TAT*         −1.77239   down   *GPM6A*       −1.287388   down
  *APOF*       −2.7681    down   *MS4A6A*      −1.02381   down   *RCL1*        −1.112209   down
  *NAT2*       −2.42415   down   *VNN1*        −1.43431   down   *CYP2B7P*     −1.31568    down
  *CLRN3*      −2.35658   down   *HSD17B2*     −1.27883   down   *CCBE1*       −1.131678   down
  *RDH16*      −2.05491   down   *FAM134B*     −1.27241   down   *LINC01093*   −1.711116   down
  *SLC25A47*   −2.3928    down   *CTH*         −1.2995    down   *ST3GAL6*     −1.008844   down
  *SLC22A1*    −2.49578   down   *ACAA1*       −1.06823   down   *TBX15*       −1.105089   down
  *THRSP*      −2.37999   down   *OTC*         −1.12724   down   *BCO2*        −1.572843   down
  *CLEC4G*     −2.8104    down   *CYP2A7*      −1.7189    down   *LUM*         −1.123456   down
  *GBA3*       −2.26827   down   *C6*          −1.48624   down   *ESR1*        −1.022446   down
  *DNASE1L3*   −2.22313   down   *GREM2*       −1.17719   down   *CYR61*       −1.101151   down
  *SHBG*       −1.96811   down   *HPD*         −1.56635   down   *HBA2*        −1.227362   down
  *LY6E*       −2.01561   down   *KBTBD11*     −1.69651   down   *KDM8*        −1.06201    down
  *CDHR2*      −2.02873   down   *CA2*         −1.30707   down   *GADD45G*     −1.126764   down
  *TMEM27*     −2.33949   down   *AKR7A3*      −1.25278   down   *ASPG*        −1.055061   down
  *C7*         −2.2597    down   *RNF125*      −1.03098   down   *FCGR2B*      −1.141195   down
  *FBP1*       −1.79884   down   *TTC36*       −1.69649   down   *ASPA*        −1.025006   down
  *SRD5A2*     −1.89056   down   *PROM1*       −1.44661   down   *PBLD*        −1.006234   down
  *MT1M*       −3.02758   down   *ADH6*        −1.22168   down   *HHIP*        −1.37843    down
  *BBOX1*      −2.04999   down   *ETNPPL*      −1.15368   down   *CRP*         −1.053533   down
  *APOA5*      −1.774     down   *HSD17B13*    −1.50866   down   *FREM2*       −1.522232   down
  *IGFBP3*     −1.70456   down   *ANXA10*      −1.62516   down   *ADRA1A*      −1.161964   down
  *ADH4*       −2.15911   down   *FXYD1*       −1.41243   down   *CNTN3*       −1.176196   down
  *KMO*        −1.91086   down   *OGDHL*       −1.30838   down   *ITLN1*       −1.034492   down
  *CYP8B1*     −1.76864   down   *PON1*        −1.17061   down   *UGT2B10*     −1.031179   down
  *CXCL14*     −2.31161   down   *ACSM3*       −1.52866   down   *DIRAS3*      −1.123875   down
  *GHR*        −2.12511   down   *SLC27A5*     −1.33347   down   *STEAP4*      −1.061309   down
  *ADGRG7*     −1.85853   down   *LIFR*        −1.47372   down   *CYP4A22*     −1.074568   down
  *MARCO*      −2.25079   down   *HABP2*       −1.06311   down   *TFPI2*       −1.00071    down
  *MT1F*       −2.59948   down   *GRAMD1C*     −1.07675   down   *MT1A*        −1.093671   down
  *CYP39A1*    −1.86139   down   *TKFC*        −1.07859   down   *RAB25*       −1.081375   down
  *OIT3*       −2.4803    down   *STEAP3*      −1.09586   down   *RDH5*        −1.006888   down
  *MBL2*       −1.62953   down   *IL1RAP*      −1.21549   down   *EPCAM*       −1.336797   down
  *VIPR1*      −1.89347   down   *GCDH*        −1.02343   down   *SPINK1*      3.633978    up
  *TDO2*       −1.44452   down   *HAL*         −1.262     down   *GPC3*        2.807155    up
  *BHMT*       −1.68706   down   *GABARAPL1*   −1.07919   down   *AKR1B10*     2.588879    up
  *PCK1*       −1.85362   down   *ID1*         −1.32236   down   *ASPM*        1.804629    up
  *MT1H*       −2.20509   down   *INMT*        −1.65209   down   *CAP2*        2.086341    up
  *AFM*        −1.90272   down   *SKAP1*       −1.06342   down   *TOP2A*       2.232845    up
  *HGFAC*      −2.18902   down   *FETUB*       −1.31249   down   *PRC1*        1.923672    up
  *MT1G*       −2.64319   down   *CFHR4*       −1.07478   down   *CDKN3*       1.778794    up
  *CYP2A6*     −2.05548   down   *HSD11B1*     −1.27605   down   *CDC20*       1.910919    up
  *CETP*       −1.77384   down   *G6PC*        −1.00804   down   *PTTG1*       1.451774    up
  *SMIM24*     −1.81333   down   *MFAP4*       −1.53268   down   *NCAPG*       1.551838    up
  *FCN2*       −1.90705   down   *ABCA8*       −1.10284   down   *LCN2*        1.551605    up
  *FOSB*       −2.12211   down   *CYP2J2*      −1.03103   down   *CCL20*       1.667526    up
  *ECM1*       −1.72876   down   *AKR1D1*      −1.77452   down   *FAM83D*      1.570755    up
  *MT1X*       −2.07498   down   *GPD1*        −1.01057   down   *KIF20A*      1.644679    up
  *SLC10A1*    −1.70131   down   *HAO1*        −1.0889    down   *PBK*         1.6372      up
  *CRHBP*      −2.55698   down   *TACSTD2*     −1.09909   down   *AURKA*       1.321582    up
  *F9*         −1.86997   down   *GCGR*        −1.51767   down   *UBE2T*       1.429052    up
  *SRPX*       −1.99247   down   *C8orf4*      −1.53773   down   *NUSAP1*      1.447842    up
  *CYP2C9*     −1.7781    down   *DMGDH*       −1.11277   down   *AKR1C3*      1.315793    up
  *GNMT*       −1.80416   down   *PON3*        −1.07722   down   *MELK*        1.397481    up
  *CYP2C8*     −1.84304   down   *MAT1A*       −1.15605   down   *SRXN1*       1.101781    up
  *PGLYRP2*    −1.57039   down   *AADAT*       −1.45288   down   *HMMR*        1.429779    up
  *LECT2*      −1.71324   down   *HPX*         −1.1201    down   *COL15A1*     1.679907    up
  *HAO2*       −2.05962   down   *KCNN2*       −1.76035   down   *UBD*         1.793116    up
  *FOS*        −2.10062   down   *ACADL*       −1.16219   down   *PLVAP*       1.303945    up
  *ANGPTL6*    −1.40198   down   *SLC13A5*     −1.18455   down   *HSPB1*       1.057592    up
  *CNDP1*      −2.19859   down   *ASS1*        −1.22714   down   *SPP1*        1.372928    up
  *CXCL12*     −1.91941   down   *PRSS8*       −1.15745   down   *CENPF*       1.339564    up
  *AGXT2*      −1.39193   down   *CPED1*       −1.24941   down   *SQLE*        1.28364     up
  *ACOT12*     −1.27878   down   *FTCD*        −1.25547   down   *CEP55*       1.130246    up
  *RSPO3*      −1.62341   down   *TMEM45A*     −1.37559   down   *KIF4A*       1.431933    up
  *PZP*        −1.76877   down   *ALDH6A1*     −1.08996   down   *TRIP13*      1.223148    up
  *COLEC10*    −1.85319   down   *SLC27A2*     −1.02491   down   *S100P*       1.428178    up
  *HOGA1*      −1.43807   down   *ETFDH*       −1.15312   down   *DLGAP5*      1.462148    up
  *MT1E*       −1.80442   down   *GCKR*        −1.00475   down   *ALDH3A1*     1.048498    up
  *CYP3A4*     −2.39818   down   *OAT*         −1.35234   down   *CDCA5*       1.222277    up
  *SLC39A5*    −1.47867   down   *SFRP5*       −1.04433   down   *SFN*         1.002947    up
  *KLKB1*      −1.57229   down   *CYP3A43*     −1.2044    down   *ESM1*        1.15394     up
  *LCAT*       −1.87391   down   *SLC6A12*     −1.11241   down   *TTK*         1.378481    up
  *IGFALS*     −1.94508   down   *SOCS2*       −1.38986   down   *TPX2*        1.091732    up
  *GLYAT*      −1.72131   down   *CYP4F2*      −1.0376    down   *PAGE4*       1.240802    up
  *ADH1C*      −1.64914   down   *PHYHD1*      −1.0017    down   *COL4A1*      1.236208    up
  *PROZ*       −1.52487   down   *SLC7A2*      −1.05182   down   *HJURP*       1.034534    up
  *CYP2E1*     −2.04247   down   *C1RL*        −1.01827   down   *RACGAP1*     1.407851    up
  *GSTZ1*      −1.39923   down   *PLG*         −1.09969   down   *IGF2BP3*     1.019851    up
  *CHST4*      −1.72521   down   *CPS1*        −1.29626   down   *ANLN*        1.53779     up
  *MFSD2A*     −1.51912   down   *ADAMTSL2*    −1.24169   down   *MCM2*        1.109517    up
  *IDO2*       −1.83679   down   *MTTP*        −1.02368   down   *UBE2C*       1.0809      up
  *SDS*        −1.75694   down   *CXCL2*       −1.43349   down   *NQO1*        1.365462    up
  *ENO3*       −1.37195   down   *HRG*         −1.00696   down   *CCNB2*       1.303069    up
  *GLS2*       −1.75439   down   *ACSL1*       −1.14524   down   *CCNA2*       1.185444    up
  *DCN*        −1.94676   down   *MAN1C1*      −1.18965   down   *MUC13*       1.14796     up
  *PLAC8*      −1.80012   down   *PCOLCE*      −1.00609   down   *MCM6*        1.016314    up
  *SERPINA4*   −1.2352    down   *MT2A*        −1.54319   down   *CENPW*       1.083208    up
  *ZG16*       −1.56869   down   *CD1D*        −1.02692   down   *TGM3*        1.050965    up
  *BCHE*       −1.77407   down   *XDH*         −1.11927   down   *RAD51AP1*    1.049223    up
  *CFP*        −1.47416   down   *PPP1R1A*     −1.10299   down   *THY1*        1.046852    up
  *SLC38A4*    −1.32606   down   *HBB*         −1.31952   down   *NUF2*        1.25884     up
  *ADH1A*      −1.27277   down   *RBP5*        −1.04885   down   *CKAP2L*      1.054397    up
  *CLEC4M*     −2.35545   down   *CFHR3*       −1.10107   down   *MAGEA1*      1.282995    up
  *CYP4A11*    −1.5036    down   *RELN*        −1.02856   down   *ECT2*        1.065576    up
  *GYS2*       −1.66608   down   *NPY1R*       −1.34248   down   *ACSL4*       1.16679     up
  *PHGDH*      −1.40019   down   *CLDN10*      −1.34641   down   *MDK*         1.076885    up
  *BGN*        −1.2236    down   *ATF5*        −1.11652   down   *PEG10*       1.104051    up
  *CIDEB*      −1.27052   down   *GNE*         −1.04957   down   *COX7B2*      1.333566    up
  *CYP2C19*    −1.55814   down   *CYP4V2*      −1.05634   down   *CCNB1*       1.362239    up
  *IYD*        −1.22582   down   *CD5L*        −1.49237   down   *RRM2*        1.542665    up
  *C8A*        −1.49471   down   *TIMD4*       −1.24178   down   *REG3A*       1.140254    up
  *STAB2*      −1.82665   down   *EGR1*        −1.41173   down   *CDK1*        1.236442    up
  *CDA*        −1.14527   down   *GADD45B*     −1.21416   down   *KIF14*       1.054151    up
  *HPGD*       −1.37821   down   *GPT2*        −1.15763   down   *ZIC2*        1.320155    up
  *OLFML3*     −1.38115   down   *ACMSD*       −1.02364   down   *BUB1B*       1.118801    up
  *PTH1R*      −1.35746   down   *CCL19*       −1.32425   down   *NDC80*       1.234218    up
  *EPHX2*      −1.29488   down   *RBP1*        −1.15142   down   *NEK2*        1.144213    up
  *COLEC11*    −1.34767   down   *ACADS*       −1.05741   down   *RBM24*       1.220962    up
  *CYP2C18*    −1.21134   down   *MYOM2*       −1.03989   down   *NMRAL1P1*    1.314053    up
  *AMDHD1*     −1.14346   down   *DCXR*        −1.01852   down   *DTL*         1.283296    up
  *LYVE1*      −1.69466   down   *PLGLB1*      −1.07364   down   *SULT1C2*     1.181554    up
  *GSPT2*      −1.16851   down   *CYP2B6*      −1.37318   down   *ROBO1*       1.247873    up
  *C8B*        −1.16715   down   *UROC1*       −1.06129   down   *SSX1*        1.001365    up
  *ADH1B*      −1.77846   down   *PDK4*        −1.08546   down   *FLVCR1*      1.006476    up
  *DPT*        −1.68413   down   *PPARGC1A*    −1.08395   down   *CTHRC1*      1.120384    up
  *AZGP1*      −1.23501   down   *NDRG2*       −1.01145   down   *ZWINT*       1.066653    up
  *ALDH8A1*    −1.37768   down   *IGF1*        −1.14785   down   *GINS1*       1.03249     up
  *RND3*       −1.62821   down   *ASPDH*       −1.15589   down   *SMPX*        1.089408    up
  *SLC19A3*    −1.18742   down   *DBH*         −1.50296   down   *GPR158*      1.061576    up
  *WDR72*      −1.27875   down   *PRG4*        −1.13337   down                             

FC, fold change.

Information on Gene Ontology (GO) enrichment analysis in biological process (BP), cellular component (CC), and molecular function (MF) categories.
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  Category   ID           Term                                                                                                                                                                                          −log~10~(FDR)   Count
  ---------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- -------
  BP         GO:0055114   Oxidation−reduction process                                                                                                                                                                   16.45646128     56
  BP         GO:0019373   Epoxygenase P450 pathway                                                                                                                                                                      12.72414085     13
  BP         GO:0006805   Xenobiotic metabolic process                                                                                                                                                                  6.801196269     16
  BP         GO:0017144   Drug metabolic process                                                                                                                                                                        6.713310124     11
  BP         GO:0045926   Negative regulation of growth                                                                                                                                                                 5.354060264     9
  BP         GO:0071276   Cellular response to cadmium ion                                                                                                                                                              4.258416753     8
  BP         GO:0042738   Exogenous drug catabolic process                                                                                                                                                              3.873727759     7
  BP         GO:0071294   Cellular response to zinc ion                                                                                                                                                                 3.86110044      8
  BP         GO:0008202   Steroid metabolic process                                                                                                                                                                     3.349012692     10
  BP         GO:0097267   Omega−hydroxylase P450 pathway                                                                                                                                                                3.048831706     6
  BP         GO:0016098   Monoterpenoid metabolic process                                                                                                                                                               2.284734835     5
  BP         GO:0007067   Mitotic nuclear division                                                                                                                                                                      1.901221899     19
  BP         GO:0006569   Tryptophan catabolic process                                                                                                                                                                  1.382839511     5
  CC         GO:0031090   Organelle membrane                                                                                                                                                                            12.13504583     21
  CC         GO:0070062   Extracellular exosome                                                                                                                                                                         10.96203625     117
  CC         GO:0005576   Extracellular region                                                                                                                                                                          8.944226201     78
  CC         GO:0005615   Extracellular space                                                                                                                                                                           8.079401711     68
  CC         GO:0072562   Blood microparticle                                                                                                                                                                           3.941029653     17
  CC         GO:0005579   Membrane attack complex                                                                                                                                                                       2.131478756     5
  MF         GO:0016705   Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen                                                                                         12.77849851     19
  MF         GO:0020037   Heme binding                                                                                                                                                                                  11.82105086     25
  MF         GO:0004497   Monooxygenase activity                                                                                                                                                                        11.5463498      18
  MF         GO:0005506   Iron ion binding                                                                                                                                                                              10.69763162     25
  MF         GO:0008392   Arachidonic acid epoxygenase activity                                                                                                                                                         10.22404973     11
  MF         GO:0019825   Oxygen binding                                                                                                                                                                                9.168975245     15
  MF         GO:0016491   Oxidoreductase activity                                                                                                                                                                       5.664542324     22
  MF         GO:0008395   Steroid hydroxylase activity                                                                                                                                                                  5.613513145     10
  MF         GO:0070330   Aromatase activity                                                                                                                                                                            2.805232257     8
  MF         GO:0004024   Alcohol dehydrogenase activity, zinc−dependent                                                                                                                                                2.38141982      5
  MF         GO:0016712   Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen   1.824019096     6
  MF         GO:0004745   Retinol dehydrogenase activity                                                                                                                                                                1.391280368     6

FDR, false discovery rate.
